Prelude Therapeutics, Lilly to Test Experimental Drug in Phase 1 Trial
Prelude Therapeutics announced a clinical trial collaboration and supply agreement with Eli Lilly to evaluate PRT13722 alongside two Lilly medicines for breast cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
BRIEF — Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2 — Breast Cancer
Oct 13 (Reuters) — Prelude Therapeutics Incorporated: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate Kat6a Selective Degrader Prt13722 In Combination With Verzenio® And Inluriyo® In Patients With Hr+/her2- Breast Cancer Prelude Therapeutics Incorporated - Agreement Supports E
Prelude, Lilly to Evaluate PRT13722 in Breast Cancer Trial
Prelude announced a clinical trial collaboration and supply agreement with Lilly to evaluate its KAT6A selective degrader PRT13722 alongside Verzenio and Inluriyo in patients with HR+/HER2- breast cancer.